Search Results

Business

CEVEC Pharmaceuticals GmbH: ROKOTE Laboratories Licenses CEVEC’s CAP(R) Ad Technology for Vaccine Manufacturing

CEVEC Pharmaceuticals GmbH (CEVEC) and ROKOTE Laboratories Finland Ltd today announced the signing of an agreement on the use of CEVEC’s proprietary CAP® Ad Technology for the manufacturing of vaccines in various indications.

September 20, 2022

·

4 min read

Deals

Cytiva strengthens cell line development with CEVEC acquisition

Global life sciences leader Cytiva has acquired CEVEC Pharmaceuticals, a leading German provider of high-performance cell line development and viral vector manufacturing technologies.

October 6, 2022

·

2 min read

Business

CEVEC and UCB Sign Agreement for the use of CEVEC’s ELEVECTA(R) AAV Manufacturing Technology in Gene Therapy

CEVEC Pharmaceuticals GmbH announced the signing of an agreement with UCB S.A. on the evaluation and use of CEVEC’s proprietary ELEVECTA Technology for the research, development, and manufacturing of Adeno-Associated Virus vectors for gene therapy applications.

September 7, 2021

·

3 min read

CEVEC Pharmaceuticals GmbH: CEVEC Closes Growth Financing Round to Serve Strong Demand in Viral Vector Technologies for Cell and Gene Therapies

CEVEC Pharmaceuticals GmbH, the leading provider of high-performance cell technology for scalable manufacturing of advanced bio-therapeutics, announced the successful closing of an internal growth financing round.

July 27, 2021

·

4 min read

Business

CEVEC Signs Agreement with Roche for the Use of CEVEC’s ELEVECTA(R) Technology in Gene Therapy

CEVEC Pharma GmbH (CEVEC) today announced the signing of an option and license agreement with Roche for the use of its newly launched ELEVECTA(R) Technology for large scale manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications.

November 10, 2020

·

4 min read

Business

CEVEC signs license agreement for the development and commercialization of exosomes for therapeutic use

CEVEC Pharmaceuticals GmbH announced the signing of a license agreement with Evox Therapeutics, Ltd. for the development and commercialization of therapeutic exosomes using CEVEC’s proprietary CAP® technology.

April 21, 2020

·

3 min read

Business

CEVEC and CARISMA Therapeutics Sign License Agreement for the Use of CAP(R) Technology in Anti-Tumor Cell Therapies

CARISMA receives full rights to use the CAP(R) Technology for the production of adenoviral vectors across their whole portfolio of cell therapies for oncology applications CEVECs unique CAP(R) cells are specifically designed for highly scalable, RCA-free adenoviral vector manufacturing in suspension bioreactors

February 2, 2021

·

4 min read

CEVEC and CellGenix announce the launch of GMP-grade TGF-ß1 for cell and gene therapy applications

CEVEC’s CAP®Go technology enables CellGenix to offer rh TGF-ß1 in preclinical and now also in GMP-grade quality, allowing a seamless transition from preclinical to clinical development and commercial manufacturing of cell therapy products

December 26, 2019

·

6 min read

Business

CEVEC’s License Partner RZNOMICS Inc. Receives Approval to Initiate Clinical Development of CAP(R) Ad Technology-Produced Gene Therapy Vector in Liver Cancer Patients

South Korean Ministry of Food and Drug Safety granted IND approval for a clinical phase 1/2a trial to evaluate safety and efficacy of RZNOMICS lead gene therapy RZ001 for the treatment of primary liver cancer.

July 13, 2022

·

5 min read

Deals

CEVEC closes major financing round to further expand and commercialize its viral vector manufacturing platform

CEVEC Pharmaceuticals GmbH announced the successful closing of a Series D financing round with new and existing investors.

April 17, 2019

·

3 min read